Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03730662 · ClinicalTrials.gov registry record · Phase 3
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,002
- Enrollment target
NCT03730662 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 2,002 participants.
The verdict
NCT03730662, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,002 participants
- Enrollment target
Study Summary
The purpose of the trial is to assess the efficacy and safety of tirzepatide taken once a week to insulin glargine taken once daily in participants with type 2 diabetes and increased cardiovascular risk. The study will last about 108 weeks and may include up to 30 visits.
Interventions
- DRUG Tirzepatide
- DRUG Insulin Glargine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,002 participants |
| Start Date | 2018-11-20 |
| Est. Completion | 2021-04-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03730662
The ClinicalTrials.gov registry entry for NCT03730662 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,002 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tirzepatide is the first listed.
NCT03730662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03730662 about?
NCT03730662 is a clinical study titled "A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk". The purpose of the trial is to assess the efficacy and safety of tirzepatide taken once a week to insulin glargine taken once daily in participants with type 2 diabetes and increased cardiovascular risk. The study will last about 108 weeks and may include up to 30 visits.
What is the current status of trial NCT03730662?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,002 participants. The study started on 2018-11-20. Estimated completion is 2021-04-22.
What interventions are being tested in trial NCT03730662?
The interventions under investigation include: Tirzepatide (DRUG), Insulin Glargine (DRUG).
Who is sponsoring clinical trial NCT03730662?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.